Human Platelet Exosome Preparation for Concentration and Size Control

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing methods for preparing exosomes from human platelets are inefficient and do not allow for precise control over exosome concentration, particle size, and growth factor content, which limits their application in clinical research and wound healing.

Innovation Solution

A method involving the use of specific buffers such as calcium ion buffer, phosphate buffered saline, Tris-HCl buffer, and HEPES buffer to treat human platelets, followed by centrifugation to obtain exosome solutions with controlled concentrations and particle sizes, and potentially enhanced growth factor content.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If conventional methods are used to prepare exosomes from human platelets, then the preparation process is simple, but the exosome concentration, particle size control, and growth factor content are insufficient

Engineering Contradiction:
Improveexosome concentration controlVSAvoidpreparation method complexity
Core Design Contradiction:
Manufacturing precisionVSDevice complexity

Solution Approach 1:

The patent applies parameter changes by systematically varying buffer composition (calcium ion concentration, pH, ionic strength), platelet activation conditions, and centrifugation parameters to precisely control exosome concentration, particle size distribution, and growth factor content. This resolves the contradiction by enabling precise manufacturing control through controlled parameter adjustments rather than complex device modifications.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent implements local quality by optimizing specific regions of the preparation process - using different buffer compositions at different stages (initial lysis buffer vs. washing buffer), creating localized conditions that favor exosome release while maintaining platelet integrity. This allows precise control over exosome characteristics without complicating the overall preparation methodology.

Inventive Principle:
Principle #3Local quality

2Quantity of substance

If conventional methods are used to prepare exosomes from human platelets, then the preparation process is quick, but the exosome concentration and growth factor content are insufficient for clinical applications

Engineering Contradiction:
Improveexosome concentrationVSAvoidpreparation time
Core Design Contradiction:
Quantity of substanceVSLoss of time

Solution Approach 1:

The patent applies preliminary action by pre-optimizing buffer composition and platelet preparation conditions before the actual exosome release process. By preparing calcium ion-containing buffers and activating platelets under controlled conditions beforehand, the method achieves high exosome concentration and growth factor content without requiring extended preparation time during the critical extraction phase.

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The patent implements continuity of useful action by maintaining platelet viability and exosome release capability throughout the preparation process. The buffered conditions preserve platelet function continuously, allowing exosomes to be released and collected in high concentration without interrupting the biological process, thereby achieving both high quantity and efficient timing.

Inventive Principle:
Principle #20Continuity of useful action

3Manufacturing precision

If conventional methods are used to prepare exosomes from human platelets, then the procedure is straightforward, but the particle size control and composition uniformity are poor

Engineering Contradiction:
Improveparticle size controlVSAvoidpreparation ease
Core Design Contradiction:
Manufacturing precisionVSEase of manufacture

Solution Approach 1:

The patent uses parameter changes to control particle size by adjusting buffer ionic strength, pH, and calcium ion concentration, which directly influence exosome budding and fusion processes. These parameter adjustments are implemented through simple buffer exchanges rather than complex equipment, maintaining ease of manufacture while achieving precise particle size control and composition uniformity.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method enables the production of exosome solutions with varied concentrations, particle sizes, and growth factor compositions, enhancing their potential for promoting cell migration and wound healing.

Implementation Method 1

treating the human platelet with a buffer to obtain a platelet solution. The buffer is calcium ion buffer, phosphate buffered saline (PBS), tris(hydroxymethyl)aminomethane hydrochloride (Tris-HCl, pH 7.0 to 8.0) buffer or 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid (HEPES) buffer.

Methodology Applied
Scientific EffectCalcium ion buffer treatment:

Implementation Method 2

centrifuging the platelet solution, and collecting supernatant of the centrifuged platelet solution to obtain an exosome solution

Methodology Applied
Scientific EffectCentrifugal separation: Centrifugal Separation

Data Source

PatentEP4582535A1Method for preparing exosomes from human platelet
Publication Date: 2025.07.09 AVENTACELL BIOMEDICAL CORP LTD
  • EP4582535A1 patent drawingFigure 1
  • EP4582535A1 patent drawingFigure 2~3
  • EP4582535A1 patent drawingFigure 4~5

AI summary

A method for preparing exosomes is provided. The method includes preparing a human platelet, treating the human platelet with a buffer to obtain a platelet solution, centrifuging the platelet solution, and collecting supernatant of the centrifuged platelet solution to obtain an exosome solution. The buffer is calcium ion buffer, phosphate buffered saline (PBS), tris(hydroxymethyl)aminomethane hydrochloride (Tris-HCl) buffer, or 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid (HEPES) buffer.